Erlotinib Impurity 2, with the CAS number 299912-59-7, is a chemical compound associated with the pharmaceutical agent erlotinib, which is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer and pancreatic cancer. As an impurity, it may arise during the synthesis or degradation of erlotinib and is typically characterized by its molecular structure, which may differ slightly from the parent compound. Impurities like Erlotinib Impurity 2 can affect the efficacy and safety of the drug, making their identification and quantification important in pharmaceutical development and quality control. The compound's characteristics, such as its molecular weight, solubility, and stability, are crucial for understanding its behavior in biological systems and its potential impact on drug formulation. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities, ensuring that they are within acceptable limits for therapeutic use.

Erlotinib iMpurity 2

299912-59-7: Erlotinib Impurity 2, with the CAS number 299912-59-7, is a chemical compound associated with the pharmaceutical agent erlotinib, which is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer and pancreatic cancer. As an impurity, it may arise during the synthesis or degradation of erlotinib and is typically characterized by its molecular structure, which may differ slightly from the parent compound. Impurities like Erlotinib Impurity 2 can affect the efficacy and safety of the drug, making their identification and quantification important in pharmaceutical development and quality control. The compound's characteristics, such as its molecular weight, solubility, and stability, are crucial for understanding its behavior in biological systems and its potential impact on drug formulation. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities, ensuring that they are within acceptable limits for therapeutic use.

Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, nesoi

CAS 299912-59-7

Erlotinib iMpurity 2

Erlotinib Related Compound A (4-(3-{[6,7-Bis(2-methoxyethoxy) quinazolin-4-yl]amino}phenyl)-2-methyl-3-butyn-2-ol hydrochloride)

Ref: 45-1241619